Orit Picard

Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases

Bella Ungar, Idan Levy, Yarden Yavne et al. · Clinical Gastroenterology and Hepatology · 2015 · 360 citations

Inflammation, Rheumatology, Mucosal Healing +12

Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease

Shomron Ben‐Horin, Matti Waterman, Uri Kopylov et al. · Clinical Gastroenterology and Hepatology · 2012 · 302 citations

Inflammation, Chronic Inflammatory Diseases, Anti-inflammatory +10

The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab

Bella Ungar, Yehuda Chowers, Miri Yavzori et al. · Gut · 2013 · 298 citations

The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful

Shomron Ben‐Horin, Miri Yavzori, Lior H. Katz et al. · Gut · 2010 · 204 citations

Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima

Shomron Ben‐Horin, Miri Yavzori, Itai Benhar et al. · Gut · 2015 · 174 citations